The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Researchers identify markers of chemotherapy resistance and outcome in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account